Similar articles

• Guidant's oops, three years later.

  Neil R. Neil R. Mater Manag Health Care. 2005 Jul;14(7):8. Mater Manag Health Care. 2005. PMID: 16146162 No abstract available.
• Medical-device safety and the FDA.

  Schultz DG. Schultz DG. N Engl J Med. 2008 Jul 3;359(1):88-9; author reply 89. doi: 10.1056/NEJMc086124. N Engl J Med. 2008. PMID: 18596278 No abstract available.
• The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?

  Basile EM, Lorell BH. Basile EM, et al. Food Drug Law J. 2006;61(2):251-72. Food Drug Law J. 2006. PMID: 16903031 No abstract available.
• Designing trials for testing prosthetic cardiac valves: a Food and Drug Administration perspective.

  Sapirstein W. Sapirstein W. Am Heart J. 2001 May;141(5):861-3. doi: 10.1067/mhj.2001.114980. Am Heart J. 2001. PMID: 11320379 Review. No abstract available.
• An overview of FDA medical device regulation as it relates to deep brain stimulation devices.

  Peña C, Bowsher K, Costello A, De Luca R, Doll S, Li K, Schroeder M, Stevens T. Peña C, et al. IEEE Trans Neural Syst Rehabil Eng. 2007 Sep;15(3):421-4. doi: 10.1109/TNSRE.2007.903973. IEEE Trans Neural Syst Rehabil Eng. 2007. PMID: 17894274 Review.